Belgian Media Stock News

Syensqo (ENXTBR:SYENS) has announced a major reshuffle of its Board of Directors, including the appointment of Heike van de Kerkhof as independent Chair. The previous chair and long serving director is stepping down as part of the changes. A new independent director with extensive industry experience is also joining the Board. For you as an investor, Board changes like these matter because they influence how Syensqo sets priorities, manages risks and oversees management. As a specialty...

Atenor (ENXTBR:ATEB) has posted its FY 2025 first half results with revenue of €53.4 million and a basic EPS loss of €0.41, while the trailing 12 month figures show revenue of €239.8 million and a basic EPS loss of €1.27. Over recent periods, revenue has shifted from €134.9 million in 2024 H1 to €174.4 million in 2024 H2 and then to €53.4 million in 2025 H1. EPS moved from a small profit of €0.01 in 2024 H1 to losses of €0.91 in 2024 H2 and €0.41 in 2025 H1, which frames the current...

Jensen-Group (ENXTBR:JEN) has put solid numbers on the table, with FY 2025 first half revenue of €263.1 million and EPS of €3.44, set against trailing 12 month revenue of €489.0 million and EPS of €5.49. Over recent reporting periods the company has seen revenue move from €227.3 million and EPS of €2.26 in the first half of 2024 to €225.9 million and EPS of €2.06 in the second half of 2024, before reaching the latest €263.1 million and €3.44. This gives investors a clear run of rising...

Latest Results Set the Stage for a Margin Story at Compagnie du Bois Sauvage Compagnie du Bois Sauvage (ENXTBR:COMB) has opened FY 2025 with first half revenue of €127.486 million and basic EPS of €3.33, following a loss making FY 2024 in which first half EPS was €34.40 in the red and second half EPS was €7.91 in the red. Over that FY 2024 period, revenue shifted from €124.713 million in the first half to €207.895 million in the second half. The trailing twelve month view into FY 2025 shows...

Viohalco (ENXTBR:VIO) has served up a mixed set of FY 2025 numbers, with Q3 total revenue at €980.1 million and a basic EPS loss of €0.16, alongside a trailing 12 month net profit margin of 2.7%. The company has seen total revenue range from €2.8 billion in Q2 2025 to €930.9 million in Q1 2025, while basic EPS moved between €0.36 in Q2 2025 and a €0.16 loss in Q3 2025. This sets the scene for investors to weigh recent earnings growth against a still thin margin profile. See our full analysis...

Cenergy Holdings (ENXTBR:CENER) has wrapped up FY 2025 with fourth quarter revenue of €514.2 million and net income of €45.8 million, set against a trailing twelve month revenue base of about €2.1 billion and net income of €193.5 million. The company has seen quarterly revenue range from €487.9 million in Q1 2025 to €534.3 million in Q2 2025, while basic EPS over the last year moved from €0.19 in Q4 2024 to as high as €0.26 in Q2 2025. This gives investors a clearer view of how changes in...

Earnings snapshot and context Elia Group (ENXTBR:ELI) has wrapped up FY 2025 with second half revenue of €2.3b and basic EPS of €2.63, while trailing twelve month figures show revenue of €4.4b and EPS of €5.51, anchoring the latest earnings release. The company has reported an increase in revenue from €2.0b in the second half of 2024 to €2.3b in the second half of 2025, with net income excluding extra items rising from €239.7m to €287.0m over the same period. This gives investors a clearer...

Van de Velde (ENXTBR:VAN) has put its latest figures on the table, with FY 2025 trailing twelve month revenue at €207.4 million and net income at €17.8 million, while the latest reported half year in 2023 showed revenue of €120.6 million, net income of €22.0 million and EPS of €1.70. The company has seen prior periods shaped by revenue of €90.7 million, net income of €11.6 million and EPS of €0.91 in the second half of 2023, and trailing EPS figures such as €2.76, €2.61 and €2.52. This points...

If you are wondering whether Umicore is still attractively priced or if its best value is already behind it, you are in the right place. The share price is at €17.76, with a 1 year return of 92.0% despite a 12.0% decline over the last 30 days and a 39.3% and 58.3% decline across the past 3 and 5 years respectively. This combination of returns can change how investors view both upside and risk. Recent coverage of Umicore has focused on its role in materials and clean tech supply chains,...

What NV Bekaert’s recent share performance tells you NV Bekaert (ENXTBR:BEKB) has drawn attention after recent trading left the shares around €42. That price sits against a mix of short term swings and steadier longer term total returns. See our latest analysis for NV Bekaert. Recent trading shows a mixed picture, with a 1 day share price return of 1.45% set against a 7 day share price return decline of 4.98%, while the 1 year total shareholder return of 30.70% points to momentum that has...

Ackermans & Van Haaren (ENXTBR:ACKB) recently reported full year 2025 results, with sales and revenue slightly below the prior year, while net income and earnings per share moved higher, putting profitability in sharper focus for investors. See our latest analysis for Ackermans & Van Haaren. The recent full year earnings release comes after a strong run in the shares, with a 22.11% 3 month share price return and 19.17% year to date. The 1 year total shareholder return of 40.73% and 5 year...

Why Lotus Bakeries is suddenly on US investors’ radar Lotus Bakeries (ENXTBR:LOTB) is drawing fresh attention after its Biscoff brand surged across US social media, with viral recipes and dessert mashups aligning with the group’s push into North American retailers. See our latest analysis for Lotus Bakeries. Those viral Biscoff posts are landing at a time when momentum in the share price has been firm, with a 34.29% 90 day share price return and a 21.63% one year total shareholder return...

DEME Group (ENXTBR:DEME) has drawn fresh attention after reporting full year 2025 results and declaring an annual dividend of €3.15 per share, with payment scheduled for May 29, 2026. See our latest analysis for DEME Group. The full year 2025 earnings update and higher dividend seem to have kept interest in the stock firm, with a 30 day share price return of 9.83% and a 90 day share price return of 26.81%. The 1 year total shareholder return of 37.96% and 3 year total shareholder return of...

Recent share performance and business snapshot Umicore (ENXTBR:UMI) has drawn investor attention after recent share price pressure, with the stock showing a 5.4% decline over the past day and a 15.1% decline over the past month. Over the past 3 months, the shares show a 9.4% total return, while the past year reflects a 108.4% total return. Over a longer horizon, 3 year and 5 year total returns are negative at 41.1% and 60.3% respectively. The company reports revenue of €19.4b and net income...

Earnings and dividend proposal draw attention to VGP (ENXTBR:VGP) VGP (ENXTBR:VGP) has come onto investors' radar after reporting full year 2025 results alongside a proposed 3% increase in its ordinary dividend to €3.40 per share. See our latest analysis for VGP. Despite a 1-day share price decline of 5.84% to €100.0 and softer 7-day and 30-day share price returns, VGP’s 1-year total shareholder return of 33.21% and 3-year total shareholder return of 26.54% point to momentum that has largely...

In February 2026, UCB SA reported full-year 2025 results showing sales of €7,388 million and revenue of €7,741 million, with net income rising to €1.56 billion and basic earnings per share from continuing operations of €8.20. Alongside this earnings improvement, UCB secured FDA approval for KYGEVVI, the first treatment for ultra-rare TK2 deficiency, and committed US$5 billion to a new US mammalian manufacturing site, reinforcing its focus on complex biologics and rare diseases. Next, we’ll...

If you are wondering whether NV Bekaert at €43.00 is genuinely good value or just looks that way on the surface, you are in the right place. Over the past year the share price has returned 29.0%, with a 3.6% gain over 30 days, even though the last 7 days saw a 1.8% decline, which can change how investors think about both upside and risk. Recent coverage of NV Bekaert has focused on the company as a long established materials player, with attention on how it is positioning itself within its...

If you are wondering whether Syensqo's current share price reflects its underlying worth, you are not alone; many investors are asking the same question right now. The stock last closed at €49.00, after declines of 36.9% over 7 days, 31.0% over 30 days, 29.9% year to date and 28.8% over the past year, which can change how the market views both its potential and its risks. Recent news coverage has focused on Syensqo as part of ongoing evergreen interest in the stock, with attention on how its...

Cmb.Tech (ENXTBR:CMBT) is back in focus after reporting fourth quarter and full year 2025 results. The company highlighted higher sales, solid profits, lower debt, and an interim dividend that puts cash returns on the table. See our latest analysis for Cmb.Tech. The latest earnings, dividend announcement and management board change have arrived alongside strong momentum, with a 30 day share price return of 14.44% and a 1 year total shareholder return of 41.69%, suggesting sentiment has been...

Proximus (ENXTBR:PROX) is back in focus after its full year 2025 earnings showed lower net income, alongside announced job reductions and a dividend cut. These moves coincided with sharp share price volatility. See our latest analysis for Proximus. The sharply negative 1 day share price return of 15.94% following the earnings release and restructuring news has erased recent gains, even though the 1 year total shareholder return is 20.86% and the 5 year total shareholder return is 38.77%...

Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis. The study met its primary endpoint with statistically significant efficacy in this patient group, which currently has limited treatment options. The data are intended to support regulatory submissions that could extend the existing VYVGART label to include ocular myasthenia gravis. Argenx is pairing these results with a broader push to expand VYVGART indications...

UCB (ENXTBR:UCB) has kicked off FY 2025 with first half revenue of €3.5b and basic EPS of €2.50, following a FY 2024 second half that delivered €3.4b in revenue and basic EPS of €4.51. The company has reported an increase in revenue from €2.8b and basic EPS of €1.10 in the first half of 2024 to the latest €3.5b and €2.50, with trailing 12 month basic EPS of €8.20 on revenue of €7.7b. For investors, that mix of higher recent earnings, stronger trailing profitability and a 20.1% net margin...

Cofinimmo (ENXTBR:COFB) has released its fourth quarter and full year 2025 results, reporting sales of €93.56 million and net income of €43.27 million for the quarter, highlighting its improved profitability. See our latest analysis for Cofinimmo. The recent earnings release comes after a strong run in the shares, with the 90 day share price return of 18.69% and year to date share price return of 15.66% adding to a 1 year total shareholder return of 66.31%. In contrast, the 5 year total...

Proximus FY 2025 results put margins and one offs in focus Proximus (ENXTBR:PROX) has wrapped up FY 2025 with fourth quarter revenue of €1.9b and net income of roughly €0m, capping a year in which trailing twelve month revenue came in at €6.6b and net income at €398m. Over recent periods the group has seen quarterly revenue move from €1.67b in Q4 2024 to €1.93b in Q4 2025. EPS across 2025 ranged from €0.26 to €0.54 per quarter, setting the backdrop for a year where earnings were also shaped...